The Use of Nootropic Drugs to Reduce Toxic Reactions in Rats to a Combination of Anti-Tuberculosis Drugs
G. N. Mozhokina,
A. G. Samoylova,
S. G. Yazeryan,
V. A. Polozkova,
M. I. Treschalin,
E. R. Pereverzeva https://doi.org/10.58838/2075-1230-2024-102-6-57-65
Abstract
The objective: to evaluate the hepatoprotective and neuroprotective activity of the nootropic drug of deanol aceglumate (nooclerin) in rats during the administration of a hepatotoxic combination of anti-tuberculosis drugs.
Subjects and Methods. Young non-linear female rats divided in 3 groups were used in this study. For 14 days, daily, rats from experimental Groups 1 and 2 received a regimen containing 5 anti-tuberculosis drugs: Mxf+ Lzd+ Cs+ Pto+ Z. Additionally, rats of Group 2 were injected with nooclerin before the administration of anti-tuberculosis drugs. Rats from Control Group received only starch suspension. Doses of anti-tuberculosis drugs and nooclerin corresponded to recommended doses for humans. The manifestation of neurotoxicity was assessed by changes in behavioral reactions according to Open Field Test, hepatotoxicity was assessed according to biochemical and morphological criteria.
Results. The hepatoprotective effect of nooclerin was confirmed by statistically significant decrease in the transaminases and bilirubin activity, which elevation was caused by anti-tuberculosis drugs, and a significant (4-fold) decrease in the severity of pathological changes in the liver tissue. Studies of behavioral reactions showed that nooclerin slightly improved the exploratory activity of rats, which was slightly reduced under the influence of anti-tuberculosis drugs.
About the Authors
G. N. Mozhokina
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health; G.F. Gause Research Institute for Development of New Antibiotics
Russian Federation
Russian Federation
Galina N. Mozhokina - Doctor of Medical Sciences, Leading Researcher of Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection, Leading Researcher of Pharmacology and Chemotherapy Laboratory, G.F. Gause Research Institute for Development of New Antibiotics
Build. 2, 4 Dostoevskiy St., Moscow, 127473
Phone +7 (495) 631-15-15
A. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of Health
Russian Federation
Russian Federation
Anastasiya G. Samoylova - Doctor of Medical Sciences, Deputy Director for Research
Build. 2, 4 Dostoevskiy St., Moscow, 127473
Phone +7 (495) 631-15-15
S. G. Yazeryan
G.F. Gause Research Institute for Development of New Antibiotics
Russian Federation
Russian Federation
Sophia G. Yazeryan - Engineer of Pharmacology and Chemotherapy Laboratory
1 Bolshaya Pirogovskaya St., Moscow, 119021
Phone: +7 (499) 246-99-80
V. A. Polozkova
G.F. Gause Research Institute for Development of New Antibiotics
Russian Federation
Russian Federation
Vasilisa A. Polozkova - Researcher of Pharmacology and Chemotherapy Laboratory
1 Bolshaya Pirogovskaya St., Moscow, 119021
Phone: +7 (499) 246-99-80
M. I. Treschalin
G.F. Gause Research Institute for Development of New Antibiotics
Russian Federation
Russian Federation
Mikhail I. Treschalin - Candidate of Medical Sciences, Researcher of Pharmacology and Chemotherapy Laboratory
1 Bolshaya Pirogovskaya St., Moscow, 119021
Phone: +7 (499) 246-99-80
E. R. Pereverzeva
G.F. Gause Research Institute for Development of New Antibiotics
Russian Federation
Russian Federation
Eleonora R. Pereverzeva - Doctor of Biological Sciences, Professor, Chief Researcher of Pharmacology and Chemotherapy Laboratory
1 Bolshaya Pirogovskaya St., Moscow, 119021
Phone: +7 (499) 246-99-80
References
1. Altshuler V.B., Kravchenko S.L., Korolkov A.I., Kozyreva A.V. On the clinical effectiveness of nooclerin (deanol aceglumate) in the treatment of patients with alcohol addiction. Narkologiya, 2013, no. 11, pp. 55-60. (In Russ.)
2. Zolotova N.V., Baranova G.V., Streltsov V.V., Kharitonova N.Yu., Akhtyamova A.A., Bagdasaryan T.R. Specific features of anti-tuberculosis chemotherapy tolerance in the light of psychological status of patients. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 4, pp. 15-19. (In Russ.)
3. Medvedev V.E. New possibilities for the treatment of asthenic disorders in psychiatric, neurological and somatic practice. Psikhiatriya I Psikhofarmakoterapiya Im. P.B. Gannushkina, 2013, no. 4, pp. 53-59. (In Russ.)
4. Mikulyak N.I., Kinzirskaya Yu.A., Mikulyak A.I. Pathogenetic rationale for the use of nooclerin (deanol aceglumate) in restoring the metabolic blood potential. Izvestiya Vysshikh Uchebnykh zavedeniy. Povolzhsky Region. Meditsinskie Nauki, 2009, vol. 11, no. 3, pp. 41-53. (In Russ.)
5. Mozhokina G.N., Zyuzya Yu.R., Petrova L.Yu., Samoylova A.G., Vasilyeva I.A. Toxicity of treatment regimens for drugresistant tuberculosis. Antibiotics and Chemotherapy, 2021, vol. 66, no. 11-12, pp. 25-30. (In Russ.) https://doi.org/10.37489/0235-2990-2021-66-11-12-25-30
6. National Program for Implementation of GLP Principles of the Organization for Economic Co-operation and Development (OECD) in Activities of Russian Testing Centers (Laboratories) in the Field of Non-Clinical Laboratory Research. (In Russ.) Available: https://fsa.gov.ru/infrastructure/nadlezhashchaya-laboratornaya-praktika-v-rossii/ Accessed October 1, 2024
7. Sukhanov D.S., Alekseeva Yu.S., Timofeev E.V. Hepatotoxic effect and metabolism of anti-tuberculosis drugs. Meditsina: Teoriya i Praktika, 2023, vol. 8, no. 2, pp. 48-62. (In Russ.)
8. Titova L.A., Pyanzova T.V. The severity of neurocognitive disorders in patients of a TB hospital. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 12, pp. 59-60. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-12-59-60
9. Brandariz-Núñez D., Hernández-Corredoira V., Guarc-Prades E, García-Navarro B. Optic neuropathy associated with linezolid: systematic review of cases. Farmacia Hospitalaria, 2019, vol. 43, no. 2, pp. 61-65.
10. Chen X., Pan H., Hao Z., Yi H., Tang S. Changing trajectories of alanine aminotransferase and risk of antituberculosis drug-induced liver injury in Chinese patients: a cohort study. J. Clin. Pharmacol., 2024, no. 4, pp. 840-848. https://doi.org/10.1002/jcph.2422
11. Court R., Centner C.M., Chirehwa M., Wiesner L., Denti P., de Vries N., Harding J., Gumbo T., Maartens G., McIlleron H. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int. J. Infect. Dis., 2021, no. 105, pp. 688-694. https://doi.org/10.1016/j.ijid.2021.03.001
12. Donald P.R. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis, 2010, vol. 90, no. 5, pp. 279-292.
13. Jones M.R., Urits I., Wolf J., Corrigan D., Colburn L., Peterson E. et al. Drug-induced peripheral neuropathy: A narrative review. Curr. Clin. Pharmacol., 2020, no. 15, pp. 38-48.
14. Lifan Z., Sainan B., Feng S., Siyan Z., Xiaoqing L. Linezolid for the treatment of extensively drug-resistant tuberculosis: A systematic review and meta-analysis. Int. J. Tuberc. Lung Dis., 2019, no. 23, pp. 1293-1307.
15. Mittal G.K., Reddy V.A.S.K., Akhtar S.M., Kaur H. Moxifloxacin induced encephalopathy in disseminated tuberculosis: A case report. Indian J. Tuberc., 2020, vol. 67, no. 3, pp. 423-425. https://doi.org/10.1016/j.ijtb.2020.05.002
16. Scavone C., Mascolo A., Ruggiero R., Sportiello L., Rafaniello C., Berrino L., Capuano A. Quinolones-induced mesculoskeletal, neurological, and psychiatric ADRs: a pharmacovigilance study based on data from the Italian Spontaneous Reporting System. Front. Pharmacol., 2020, no. 11, pp. 428.
17. Wang N., Chen X., Hao Z., Guo J., Wang X., Zhu X., Yi H., Wang Q., Tang S. Incidence and temporal trend of antituberculosis drug-induced liver injury: a systematic review and meta-analysis. J. Trop. Med., 2022, no. 4, pp. 8266878. https://doi.org/10.1155/2022/8266878
18. Wierzbiński P., Hubska J., Henzler M., Kucharski B., Bieś R., Krzystanek M. Depressive and other adverse CNS effects of fluoroquinolones. Pharmaceuticals (Basel), 2023, vol. 16, no. 8, pp. 1105. https://doi.org/10.3390/ph16081105
19. Xu L., Zhang F., Xu C., Liu K., Wu W., Tian Y. Is the prophylactic use of hepatoprotectants necessary in antituberculosis treatment? Chemotherapy, 2017, vol. 62, no. 5, pp. 269-278.
20. Wu S., Xia Y., Lv X. et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of antituberculosis agents in a large cohort of Chinese patients. Journal of Gastroenterology and Hepatology, 2015, vol. 30, no. 3, pp. 540-545. https://doi.org/10.1111/jgh.12717
21. Zhang S., Pan H., Peng X. et al. Preventive use of a hepatoprotectant against antituberculosis drug-induced liver injury: a randomized controlled trial. Journal of Gastroenterology and Hepatology, 2016, vol. 31, no. 2, pp. 409-416. https://doi.org/10.1111/jgh.13070
22. Zhang Z., Cheng Z., Liu Q. et al. Safety of longer linezolid regimen in children with drug-resistant tuberculosis and extensive tuberculosis in Southwest China. J. Glob. Antimicrob. Resist., 2020, no. 21, pp. 375-379. https://doi.org/10.1016/j.jgar.2019.09.019
Review
For citations:
Mozhokina G.N., Samoylova A.G., Yazeryan S.G., Polozkova V.A., Treschalin M.I., Pereverzeva E.R. The Use of Nootropic Drugs to Reduce Toxic Reactions in Rats to a Combination of Anti-Tuberculosis Drugs. Tuberculosis and Lung Diseases. 2024;102(6):57-65. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-6-57-65
Views:
196
Email this article 